The sterile drug product testing market is seeing steady growth as demand for injectable and biologic drugs surges. Strict regulatory standards from the FDA and EMA are driving pharmaceutical companies to invest heavily in quality control and sterility assurance. Combined with technological advancements and expansion in emerging markets, these factors are shaping a dynamic landscape for sterile drug testing worldwide.
In 2024, North America captured 47.8% of the market share, supported by a strong pharmaceutical industry and stringent regulatory practices. Meanwhile, Asia-Pacific is poised for the fastest growth in the coming years as regional pharmaceutical manufacturing expands.
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5803
Sterility Testing dominated in 2024 with a 38.5% revenue share, thanks to its mandatory role in ensuring product safety.
Container Closure Integrity Testing (CCIT) is set to grow at the fastest rate as manufacturers focus on advanced packaging solutions.
Instruments held the largest share (46.2%) among products and services in 2024, while Reagents & Kits are expected to grow rapidly due to demand for standardized testing solutions.
The injectables segment led with a 54.7% market share because of their high sensitivity to contamination. The rising popularity of pre-filled syringes and autoinjectors for self-administered therapies is also driving demand for rigorous sterile testing.
Modern advancements like automation, real-time monitoring, and AI-powered quality control are revolutionizing sterile drug testing:
Faster Results: Rapid microbiological methods (RMMs) cut testing time dramatically. For example, Nelson Labs’ RMM delivers sterility results in just 6 days compared to the traditional 14.
AI Integration: AI-driven systems improve data analysis, predictive maintenance, and contamination risk detection, streamlining workflows and supporting faster batch release.
Robotics & Automation: These reduce human error and enhance consistency in sterility assurance.
Symbiosis Pharmaceutical Services invested $1.25 million in December 2023 to expand in-house analytical and microbiological testing.
Charles River Laboratories launched Accugenix NGS in May 2023 for faster and more accurate microbial identification.
Thermo Fisher Scientific opened a new sterile drug manufacturing facility in Singapore in May 2023, boosting capacity in Asia-Pacific.
Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5803
The increasing production of biologics and injectable therapies demands stringent sterility validation. For example, Johnson & Johnson’s $2 billion biologics facility in North Carolina, announced in October 2024, highlights this trend.
Rapid methods, such as Samsung Biologics’ adoption of Growth Direct in January 2024, are gaining traction for their ability to speed up product release and ensure compliance.
Dominated the market with robust R&D, regulatory oversight, and advanced manufacturing infrastructure.
Driven by EMA regulations and strong demand for biologics. Germany, France, and the UK lead adoption of advanced testing methods.
Expected to see the fastest growth as countries like India scale pharmaceutical manufacturing and export sterile formulations globally.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
In March 2025, Nelson Labs expanded its rapid microbiological methods across labs in the US and Europe, cutting sterility testing times and supporting faster product launches.
Sterile drug product testing ensures pharmaceutical products like injectables and biologics are free of viable microorganisms. It is critical for patient safety and regulatory compliance, particularly for products directly introduced into the body.
The market is growing due to rising demand for biologics and injectables, stricter regulatory standards, technological advancements in testing methods, and the expansion of pharmaceutical manufacturing in emerging markets.
AI enhances accuracy, speeds up data analysis, predicts equipment maintenance needs, and reduces contamination risks. This helps companies improve quality assurance and meet regulatory requirements efficiently.
North America leads the market with a 47.8% share in 2024, while Asia-Pacific is expected to grow at the fastest rate due to rising pharmaceutical production and exports.
Trends include rapid microbiological testing methods, increased automation, AI integration, and the expansion of sterile manufacturing facilities worldwide.
To access the full market report : https://www.towardshealthcare.com/price/5803
Sustainable manufacturing is rapidly evolving as industries embrace green technologies. At the forefront of this transformation is bioprocessing, which uses… Read More
The contamination detection in pharmaceutical products market is experiencing remarkable growth in 2025. This surge is driven by strict government… Read More
The demand for CDMO (Contract Development and Manufacturing Organization) services in the pharmaceutical and biotechnology industries is rising sharply. As… Read More
The CAR T-cell neurotoxicity detection market is witnessing remarkable growth as the adoption of CAR T-cell therapies accelerates worldwide. These… Read More
The global testicular implants (prosthesis) market is projected to grow significantly, reaching USD 7.55 billion by 2034 from USD 3.8… Read More
The robotics in drug discovery market is undergoing a transformative shift, driven by the growing need for speed, accuracy, and… Read More